Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRODIGE 61 / FFCD 1702 / FUNGEMAX
2024-518143-38-00Phase 3Authorised
- Sponsor
- Fédération Francophone de Cancérologie Digestive
- Start
- Oct 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised trial of irinotecan, gemcitabine, nab-paclitaxel, fluorouracil and folinic acid in pancreatic adenocarcinoma (PDAC) (3 arms), sponsored by Fédération Francophone de Cancérologie Digestive. Primary endpoint: Progression-free survival at 6 months. Planned start Oct 2024; status: authorised.
02
Drugs
irinotecangemcitabinenab-paclitaxelfluorouracilfolinic acid
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2024-518143-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518143-38-00.